Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
about
RNA-associated protein 55 (RAP55) localizes to mRNA processing bodies and stress granulesAutoimmune liver serology: current diagnostic and clinical challengesAutoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis.Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patientsAntinuclear antibodies as ancillary markers in primary biliary cirrhosis.Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body.Tracing environmental markers of autoimmunity: introducing the infectome.Primary biliary cirrhosis: family storiesLMKB/MARF1 localizes to mRNA processing bodies, interacts with Ge-1, and regulates IFI44L gene expression.Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies.Popular and unpopular infectious agents linked to primary biliary cirrhosis.Probing the mRNA processing body using protein macroarrays and "autoantigenomics".Epstein-barr virus as a trigger of autoimmune liver diseases.Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays.Risk factors for hepatic decompensation in patients with primary biliary cirrhosisCurrent Concepts in Primary Biliary Cirrhosis and Primary Sclerosing CholangitisEtiopathogenesis of primary biliary cirrhosis.The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis.Serum autoantibodies for the diagnosis and management of autoimmune liver diseases.Primary biliary cirrhosis in adults.Mechanisms of tissue injury in autoimmune liver diseases.PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis.Molecular diagnostics of primary biliary cirrhosis.Natural history of primary biliary cirrhosis.Detection of anti-SP100 antibodies in primary biliary cirrhosis. Comparison of ELISA and immunofluorescence.Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Guidelines for the management of primary biliary cirrhosis
P2860
Q24305036-B6114A6B-7C98-4824-BBAE-48BDAFB7BB01Q24644140-7F26FA4A-FF76-484E-BC95-21A8CBD962C2Q33751665-C3BC4A60-7A62-48DC-BD45-756108499482Q34213743-3FE33E44-97C1-416E-9C8B-DFC7E65D8007Q34237440-8697A63C-A1DC-4094-BB6A-DD066F75E449Q34366701-5EC43EDD-F406-4059-B78E-314A0553B273Q34671373-A41273B7-2F3D-4690-B92F-9B72292CFEE3Q35038800-DF3E030E-C89E-4FCD-A16E-778BBB1C4F77Q35155260-40F290BA-3CAA-43F2-AEE0-BCA61AA277C8Q35309854-CCC0239E-9FD6-4E2F-B13C-F72622E1A70AQ35309882-C14AA6E5-A81F-4CC3-9324-1438D98077BFQ35752843-4C8F85DA-1BD9-40A3-BDE9-E1996F1A7BA0Q36010920-4CE4BD9B-C62D-4664-898E-70DC52333946Q36211824-9E25DC60-5B8C-4B0E-86FB-C54F0EA854BDQ36637728-DE6F087F-7273-44BE-B1B8-58A9CED87A30Q36752084-6C7ED181-4A5C-4BA4-B86D-F3163EF75C91Q37182941-ED4ABFEF-DFB0-4F0B-8612-23E13A34B17BQ37388844-140C12C4-7853-4549-A178-7CF940DE6321Q38067132-A367C3A3-B911-4C18-8B92-D5DE0D82F021Q38192045-7585A870-0F9D-4923-B867-51D190C64889Q38235918-8A042156-6061-4DC6-8959-B8A930A046F0Q39782708-B0A806B0-FE2F-4CC4-BADA-0ED52B36C023Q40086159-7C15C208-E709-4577-9EB6-927E0A635E68Q46608065-154627A0-2B2A-4549-B9F7-CB3C5E4E8CB4Q47997622-1999C079-B3F7-44B9-854E-72E4E9E1F6D1Q50897757-FA4FB306-943A-4A32-B8FC-F099B47CC278Q52624982-22DA2259-4595-4906-BD0F-E81C5E019420Q56429943-137CC1A1-E1F9-42E2-BB92-81BA9E1870A7
P2860
Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Do antinuclear antibodies in p ...... reased risk for liver failure?
@en
Do antinuclear antibodies in p ...... reased risk for liver failure?
@nl
type
label
Do antinuclear antibodies in p ...... reased risk for liver failure?
@en
Do antinuclear antibodies in p ...... reased risk for liver failure?
@nl
prefLabel
Do antinuclear antibodies in p ...... reased risk for liver failure?
@en
Do antinuclear antibodies in p ...... reased risk for liver failure?
@nl
P2093
P1476
Do antinuclear antibodies in p ...... reased risk for liver failure?
@en
P2093
Ayako Nakajima
Donna Neuberg
Jiang Hong Yu
Keith Lindor
Wei-Hong Yang
P304
P356
10.1016/S1542-3565(04)00465-3
P407
P577
2004-12-01T00:00:00Z